Hepatitis E epidemiology and demographics

Revision as of 21:46, 27 August 2014 by Joao Silva (talk | contribs) (→‎Race)
Jump to navigation Jump to search

Hepatitis E Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Hepatitis E from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis E epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis E epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis E epidemiology and demographics

CDC on Hepatitis E epidemiology and demographics

Hepatitis E epidemiology and demographics in the news

Blogs on Hepatitis E epidemiology and demographics

Directions to Hospitals Treating Hepatitis E

Risk calculators and risk factors for Hepatitis E epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Prevalence

Incidence

Age

The rate of anti-HEV antibodies increases with age. According to a survey conducted in the US from 1988 to 1994, this rate can range from 10% (6 to 10 years) to 40% (>60 years).[1]

Gender

Pregnant Women

Although pregnant women have the same exposure to the virus as other people, due to their micronutrient status and cytokine levels, they are more prone to the severe form of the disease. [2]

Race

After adjusting to age, the rate of anti-HEV antibodies was noted to be higher in non-hispanic whites (22.1%) than among blacks (14.5%).[1]

Developed Countries

The rate of anti-HEV antibodies is lower than in developing countries. [2]

Developing Countries

Hepatitis E may occur either as a sporadic case, or as an epidemic disease. It is often caused by genotypes 1 (Asia) and 2 (Central America and Africa).[3] Anti-HEV antibodies were detected in 30 to 80% of adults.[2]

References

  1. 1.0 1.1 Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE (2009). "Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994". J Infect Dis. 200 (1): 48–56. doi:10.1086/599319. PMC 2762746. PMID 19473098.
  2. 2.0 2.1 2.2 Hoofnagle JH, Nelson KE, Purcell RH (2012). "Hepatitis E." N Engl J Med. 367 (13): 1237–44. doi:10.1056/NEJMra1204512. PMID 23013075.
  3. Purcell RH, Emerson SU (2008). "Hepatitis E: an emerging awareness of an old disease". J Hepatol. 48 (3): 494–503. doi:10.1016/j.jhep.2007.12.008. PMID 18192058.